Price paid for Mas Orange is good. Buy reiterated.

Good beat in Q3 and guidance increased - BUY confirmed.

Strong Q3 results. FY outlook confirmed.

Massive beat in Q3. FY estimates are likely to be increased.

Decent beat in Q3 Sales- FY guidance lifted.

Novartis acquires a US-based neuroscience company for $12bn.